Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Trial Details

NCT ID
NCT07491445
Phase
PHASE3
Sponsor
Revolution Medicines, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • daraxonrasib
  • gemcitabine
  • nab-paclitaxel
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Tampa, Florida, United States|27.94752,-82.45843
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Henderson, Nevada, United States|36.0397,-114.98194

Key Eligibility Criteria

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed pancreatic adenocarcinoma.
  • Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →